TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Large Decrease in Short Interest

Posted by Financial News Live on Nov 27th, 2024

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 215,500 shares, a decrease of 71.0% from the October 31st total of 743,600 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average daily trading volume, of 1,680,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of TransCode Therapeutics in a research note on Friday, November 15th.

Check Out Our Latest Research Report on RNAZ

TransCode Therapeutics Trading Down 9.8 %

Shares of NASDAQ RNAZ traded down $0.04 during midday trading on Wednesday, reaching $0.34. 471,795 shares of the stock were exchanged, compared to its average volume of 1,227,853. TransCode Therapeutics has a 12 month low of $0.22 and a 12 month high of $18.66. The business has a 50-day simple moving average of $0.50 and a two-hundred day simple moving average of $0.66.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC acquired a new stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned 0.84% of TransCode Therapeutics as of its most recent filing with the SEC.

TransCode Therapeutics Company Profile

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.